Emerging cardiological issues during the COVID-19 pandemic.
作者信息
Everaert Bert R, Muylle Jan, Bartholomeus Twickler Theodorus
机构信息
Department of Cardiology, AZ Monica Hospital, Antwerp, Belgium.
Department of Intensive Care, AZ Monica Hospital, Antwerp, Belgium.
出版信息
Eur J Clin Invest. 2020 Jul;50(7):e13270. doi: 10.1111/eci.13270. Epub 2020 Jun 17.
Abstract
摘要
相似文献
1
Emerging cardiological issues during the COVID-19 pandemic.新型冠状病毒肺炎大流行期间出现的心脏问题
Eur J Clin Invest. 2020 Jul;50(7):e13270. doi: 10.1111/eci.13270. Epub 2020 Jun 17.
2
Left ventricular dysfunction in COVID-19: A diagnostic issue.新型冠状病毒肺炎中的左心室功能障碍：一个诊断问题。
Anaesth Crit Care Pain Med. 2020 Jun;39(3):393-394. doi: 10.1016/j.accpm.2020.05.015. Epub 2020 Jun 17.
3
Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment.探索性新冠肺炎治疗中药物相互作用对QTc的影响因素
Circulation. 2020 Jun 16;141(24):e906-e907. doi: 10.1161/CIRCULATIONAHA.120.047521. Epub 2020 Apr 8.
4
SARS-CoV 2 Infection (Covid-19) and Cardiovascular Disease in Africa: Health Care and Socio-Economic Implications.SARS-CoV-2 感染（COVID-19）与非洲心血管疾病：医疗保健和社会经济影响。
Glob Heart. 2021 Mar 15;16(1):18. doi: 10.5334/gh.829.
5
Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same.药物性肝损伤与新型冠状病毒肺炎感染：规则依旧相同。
Drug Saf. 2020 Jul;43(7):615-617. doi: 10.1007/s40264-020-00954-z.
6
Psychiatric implications of the use of hydroxychloroquine in COVID-19 patients.新冠病毒疾病（COVID-19）患者使用羟氯喹的精神科影响
Indian J Pharmacol. 2020 May-Jun;52(3):229-231. doi: 10.4103/ijp.IJP_595_20. Epub 2020 Aug 4.
7
Immune-Mediated Coagulopathy in COVID-19 Infection.新型冠状病毒肺炎感染中的免疫介导性凝血病
Semin Thromb Hemost. 2020 Oct;46(7):838-840. doi: 10.1055/s-0040-1714272. Epub 2020 Sep 2.
8
Current data on the cardiovascular effects of COVID-19.关于新冠病毒病心血管影响的当前数据。
Hellenic J Cardiol. 2020 Jan-Feb;61(1):46-48. doi: 10.1016/j.hjc.2020.04.001. Epub 2020 Apr 18.
9
Low hospitalization rate without severe arrhythmias: a prospective survey on 350 patients early home treated with hydroxychloroquine during COVID-19 pandemic.无严重心律失常的低住院率：COVID-19大流行期间对350例早期在家接受羟氯喹治疗患者的前瞻性调查。
J Cardiovasc Med (Hagerstown). 2020 Nov;21(11):922-923. doi: 10.2459/JCM.0000000000001061.
10
The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.接受羟氯喹和阿奇霉素治疗的新冠肺炎患者的QT间期。
Nat Med. 2020 Jun;26(6):808-809. doi: 10.1038/s41591-020-0888-2.
引用本文的文献
1
The therapeutic potential of regulatory T cells in reducing cardiovascular complications in patients with severe COVID-19.调节性 T 细胞在降低重症 COVID-19 患者心血管并发症方面的治疗潜力。
Life Sci. 2022 Apr 1;294:120392. doi: 10.1016/j.lfs.2022.120392. Epub 2022 Feb 8.
2
The importance of myocarditis in Covid-19.心肌炎在新冠病毒疾病中的重要性。
Health Sci Rep. 2022 Jan 13;5(1):e488. doi: 10.1002/hsr2.488. eCollection 2022 Mar.
3
Cardiovascular RNA markers and artificial intelligence may improve COVID-19 outcome: a position paper from the EU-CardioRNA COST Action CA17129.心血管 RNA 标志物和人工智能可能改善 COVID-19 结局：来自 EU-CardioRNA COST 行动 CA17129 的立场文件。
Cardiovasc Res. 2021 Jul 7;117(8):1823-1840. doi: 10.1093/cvr/cvab094.
4
The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics.寻找 SARS-CoV-2/COVID-19 治疗方法的艰难途径。
J Antimicrob Chemother. 2020 Sep 1;75(9):2381-2383. doi: 10.1093/jac/dkaa272.
本文引用的文献
1
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.肾素-血管紧张素-醛固酮系统抑制剂与新冠病毒风险。
N Engl J Med. 2020 Jun 18;382(25):2441-2448. doi: 10.1056/NEJMoa2008975. Epub 2020 May 1.
2
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19.心血管疾病、药物治疗与新冠病毒感染相关死亡率
N Engl J Med. 2020 Jun 18;382(25):e102. doi: 10.1056/NEJMoa2007621. Epub 2020 May 1.
3
ST-Segment Elevation in Patients with Covid-19 - A Case Series.新型冠状病毒肺炎患者的ST段抬高——病例系列
N Engl J Med. 2020 Jun 18;382(25):2478-2480. doi: 10.1056/NEJMc2009020. Epub 2020 Apr 17.
4
Incidence of thrombotic complications in critically ill ICU patients with COVID-19.COVID-19 重症监护病房危重症患者的血栓并发症发生率。
Thromb Res. 2020 Jul;191:145-147. doi: 10.1016/j.thromres.2020.04.013. Epub 2020 Apr 10.
5
Typical takotsubo syndrome triggered by SARS-CoV-2 infection.由新型冠状病毒肺炎（SARS-CoV-2）感染引发的典型应激性心肌病
Eur Heart J. 2020 May 14;41(19):1860. doi: 10.1093/eurheartj/ehaa306.
6
Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection.一名感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的患者出现急性心肌炎，表现为反向Tako-Tsubo综合征。
Eur Heart J. 2020 May 14;41(19):1861-1862. doi: 10.1093/eurheartj/ehaa286.
7
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.新冠病毒病患者中的肾素-血管紧张素-醛固酮系统抑制剂
N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.
8
Antihypertensive drugs and risk of COVID-19?抗高血压药物与新冠病毒病风险？
Lancet Respir Med. 2020 May;8(5):e30-e31. doi: 10.1016/S2213-2600(20)30153-3. Epub 2020 Mar 26.
9
Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19).COVID-19 患者的致命结局对心血管的影响。
JAMA Cardiol. 2020 Jul 1;5(7):811-818. doi: 10.1001/jamacardio.2020.1017.
10
Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China.新冠肺炎住院患者中心脏损伤与死亡的相关性研究：中国武汉。
JAMA Cardiol. 2020 Jul 1;5(7):802-810. doi: 10.1001/jamacardio.2020.0950.
Zotero 插件